Gonorrhoea Antimicrobial Surveillance Programme (GASP)
WHO Gonococcal Surveillance Programme in the Western Pacific Region
Surveillance is essential to optimize treatment recommendations and detect emerging antimicrobial resistance (AMR). A majority of developed countries have established AMR surveillance systems. However, many countries lack data, especially those with high burden rates.
The WHO Gonococcal Surveillance Programme (GASP) in the Western Pacific Region, coordinated from Sydney, Australia, has been operative since 1992 and has provided information to optimize antibiotic treatment for gonorrhoea in the Region. There are currently 20 countries participating with 24 laboratories reporting. The participating laboratories conduct susceptibility testing and incorporate quality control (e.g. control panels) and participate in the external quality assurance system (EQAS) programme. Participating laboratories send AMR data to the WHO Collaborating Centre for Sexually Transmitted Diseases in Sydney, Australia where data are analysed, and a report is written and published in a peer review journal.
The WHO EQAS programme includes dispatching a set of gonococci each year as unknowns to each participating laboratory in the Western Pacific and South-East Asia Regions.